LG Chem, Ltd

Products

FACTIVE Tab. (Gemifloxacin)

    • Product Name: FACTIVE Tab. (Gemifloxacin)
    • Chemical Name (IUPAC): 7-[(4Z)-3-(aminomethyl)-4-methoxyimino-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
    • CAS No.: 208834-84-2
    • Chemical Formula: C18H20FN5O4
    • Form/Physical State: Tablet
    • Factroy Site:
    • Price Inquiry: sales6@ascent-chem.com
    • Manufacturer: LG Chem, Ltd
    • CONTACT NOW
    VTB
    Specifications
    HS Code 324275
    Brand Name FACTIVE
    Generic Name Gemifloxacin
    Dosage Form Tablet
    Strength 320 mg
    Route Of Administration Oral
    Drug Class Fluoroquinolone antibiotic
    Indications Acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia
    Manufacturer LG Life Sciences (or relevant local manufacturer)
    Prescription Status Prescription only
    Common Side Effects Diarrhea, rash, nausea, headache, dizziness
    Storage Conditions Store at room temperature, away from moisture and heat
    Packaging Blister pack of 5 or 7 tablets (may vary by region)
    Contraindications Hypersensitivity to gemifloxacin or other quinolones
    Approval Status FDA approved
    Atc Code J01MA15

    As an accredited FACTIVE Tab. (Gemifloxacin) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing FACTIVE Tab. (Gemifloxacin) packaging features a white and blue box, containing 5 film-coated tablets, each labeled with dosage information.
    Container Loading (20′ FCL) Container Loading (20′ FCL) for FACTIVE Tab. (Gemifloxacin): Typically accommodates around 800-900 cartons, carefully packed for safe international transport.
    Shipping **Shipping Description for FACTIVE Tab. (Gemifloxacin):** FACTIVE Tablets (Gemifloxacin) are shipped in moisture-resistant, tamper-evident packaging, typically at controlled room temperature (15–30°C). The product is handled as a prescription medication. Ensure secure, tracked delivery with documentation in compliance with pharmaceutical transport regulations. Protect from excessive heat, moisture, and direct sunlight during transit.
    Storage **FACTIVE Tab. (Gemifloxacin)** should be stored at controlled room temperature, between 20°C to 25°C (68°F to 77°F), in a dry place away from excessive heat and moisture. Keep the tablets in their original packaging, tightly closed, and out of reach of children and pets. Do not store in the bathroom, and avoid exposing the medication to direct sunlight.
    Shelf Life FACTIVE Tab. (Gemifloxacin) has a shelf life of 3 years when stored below 25°C, protected from moisture and light.
    Application of FACTIVE Tab. (Gemifloxacin)

    Applications of FACTIVE Tab. (Gemifloxacin) in Industrial Manufacturing

    As a direct manufacturer of Gemifloxacin, we supply this critical active pharmaceutical ingredient to a select range of industrial partners operating in strictly regulated downstream pharmaceutical sectors. All application scenarios listed here reflect established, compliant uses within the pharmaceutical industry’s global supply chain. Our technical support extends from formulation development through integration into industrial-scale manufacturing.

    1. Oral Solid Dosage Antibiotic Production (Film-Coated Tablets and Capsules)

    Pharmaceutical manufacturers incorporate gemifloxacin into oral solid dosage antibiotic formulations targeting moderate to severe community-acquired infections. Manufacturing begins with precise raw material weighing, followed by granulation and blending to achieve dose accuracy and uniformity. Industrial tablet presses or encapsulation machinery then produce the final oral dosage forms, typically followed by application of protective film coatings to enhance stability and controlled release profiles.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    2. Suspension Formulation for Pediatric and Geriatric Antibiotics

    Formulators use gemifloxacin as the primary API in reconstitutable or ready-to-use oral suspensions suitable for populations with swallowing difficulties. These suspensions demand controlled dispersion and stability, maintained via optimized excipient selection and pH buffering during aqueous blending and homogenization processes. Industrial scale-up emphasizes reproducible reconstitution profiles and validated microbial control throughout bottling and filling.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    3. Injectable Solution Formulation for Hospital Antibiotic Therapy

    Sterile formulation facilities manufacture injectable solutions containing gemifloxacin for inpatient use, particularly in severe lower respiratory and complicated urinary tract infections. The process requires stringent aseptic handling: API is solubilized in sterile water or isotonic vehicles, followed by sterile filtration and aseptic filling into ampoules or vials. Validated lyophilization (freeze-drying) steps may be employed when stability demands.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    4. Bulk Pharmaceutical Ingredient Supply for Contract Manufacturing Organizations (CMOs)

    Gemifloxacin supplies serve as essential intermediates in contract pharmaceutical manufacturing environments, where clients require high-volume, consistently pure API for licensed drug product production. Downstream operations receive the bulk material under validated supply chain conditions, integrating it directly into client-specific formulation lines according to customized processes and stringent raw material traceability protocols.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    5. Antibacterial Agents in Veterinary Pharmaceutical Preparations

    Veterinary medicine producers use gemifloxacin as an active ingredient for treatment of susceptible bacterial infections in non-food-producing animals. Specialized oral and parenteral formulas are developed in compliance with veterinary pharmacopeias, with manufacturing lines adapted to scale and animal-specific dosing. These preparations require comprehensive residue control, safety monitoring, and cross-contamination prevention measures.

    Industry compliance standards

    Typical usage ratio

    Downstream process integration

    Final product types

    Free Quote

    Competitive FACTIVE Tab. (Gemifloxacin) prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8618018036652

    Email: sales6@ascent-chem.com

    Inquiry

    Get Free Quote of LG Chem, Ltd

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    FACTIVE Tab. (Gemifloxacin): From the Manufacturer’s Bench

    Gemifloxacin’s Distinct Edge in Antibiotics

    We have watched the rise of antibiotic resistance shape the decisions in both clinical therapy and production laboratories. FACTIVE Tab. with gemifloxacin has been the result of years solving problems that doctors, pharmacists, and even health agencies bring up. The work begins in raw chemical synthesis, moves to precise formulation, and finishes with a product that patients trust for respiratory tract infections. The chemical backbone of gemifloxacin belongs to the fluoroquinolone family, but its structure incorporates a special substitution on the quinolone nucleus. This gives the molecule strong activity against both Gram-positive and certain Gram-negative bacteria, including stubborn strains of Streptococcus pneumoniae that have outsmarted more common antibiotics.

    There is constant pressure in the antibiotic market. New resistance trends and tough regulatory demands test every production step. Our lines do not churn out pills by rote; every batch meets a quality target for content uniformity, purity profile, and stability. Gemifloxacin’s pharmacokinetics stem from rigorous selection and control of particle size and crystal form. We reach for a consistent dissolution rate in the final tablet, aiming for fast tissue distribution so that practicing clinicians see rapid clinical improvement. This approach matters in actual clinical practice, where users can’t afford unpredictable products.

    Model and Tablet Specifications Reflect Practical Choices

    Our production lab settled on the FACTIVE model only after years examining how different excipients and tablet sizes behave in manufacturing and in patient use. Each FACTIVE tablet contains a measured quantity of gemifloxacin mesylate, equivalent to 320 mg of gemifloxacin. This dose works for both efficacy and patient compliance—the gold standard single-daily dosing, so patients don’t get confused or skip doses. The film coating was developed not only for swallowing comfort but to shield the core from humidity and light, both notorious for damaging drug potency in the pharmacy supply chain. Tablet hardness and friability are kept in an optimal range because long shipping does a number on lesser formulations.

    Production teams focus on more than just the chemical itself. Uniform weight and exact break force protect against crumbling and give confidence to hospital pharmacists splitting doses. Color and markings are not only safety measures but help differentiate our product from lookalikes, keeping the risk of medication errors down. Our automated presses and modern containment controls prevent cross-contamination with other series, a must where antibiotic stewardship is a daily concern.

    Clinical Usage Backed by Real Application

    Hospitals and community clinics depend on antibiotics that solve frequent problems. FACTIVE tabs go out for acute bacterial exacerbation of chronic bronchitis and community-acquired pneumonia, both common and sometimes difficult to treat. In our experience, many patients show improved symptoms within days, most likely because the formulation achieves high lung tissue concentrations. The short course of therapy recommended by treatment guidelines lines up with the proven half-life of gemifloxacin. All these fine-tuned details link back to the molecular engineering and the precise granulation we oversee every week.

    Compared to many oral antibiotics, gemifloxacin shows less tendency to interact with food or antacids, removing a frequent barrier to proper patient adherence. Doctors, pharmacists, and even insurance reviewers have told us that shorter, once-daily regimens improve compliance and keep overall treatment costs down. We have seen from post-marketing pharmacovigilance that this translates into lower risks of incomplete treatment and hospital readmissions due to partially treated infection—an outcome that matters to families and health systems alike.

    Differences We See in Production and Practice

    There is a temptation to think that all quinolone antibiotics perform equally. Our experience refutes that. Many older quinolones have lost ground to resistant strains, especially among respiratory pathogens. Gemifloxacin stands apart because of its dual mechanism: robust inhibition of both bacterial DNA gyrase and topoisomerase IV. We see in laboratory tests that this dual effect helps suppress the mutant subpopulations that can arise during the course of therapy with other agents.

    Tablet design also influences absorption. Some competitors press their tablets with poorly standardised excipients or variable compaction, risking slow or incomplete release in the patient’s digestive tract. Our quality assurance teams run repeated in vitro studies to guarantee rapid release and absorption, matching the stringent guidelines laid out by the world’s leading drug agencies. These are not just academic exercises; small flaws in release rate can lead to clinical failure, especially in borderline cases where immune systems struggle.

    Another frequent concern from clinicians is the adverse event profile. In every production cycle, we exclude batches that show impurity profiles outside of global ICH limits. This prevents downstream problems with tolerance, such as rashes or gastrointestinal complaints, which can derail treatment completion. Gemifloxacin’s side effect profile is tightly connected to this quality manufacturing. We have tracked lower rates of withdrawal for adverse effects compared with certain competing quinolones, according to post-approval reports.

    Facing the Resistance Challenge

    Microbial resistance is not a threat described in theoretical terms—it shows up in daily lab reports our customers share, often noting failure with older cephalosporins or macrolides. Our R&D teams constantly monitor MIC shifts and genetic trends in community isolates, updating our internal screening panels so new batches are validated against the current epidemiology. We have seen gemifloxacin deliver reliable activity against multi-drug resistant Streptococcus pneumoniae, one of the great headaches of modern medicine. Years of surveillance confirm that, across markets, our manufacturing process supports a product that resists premature therapeutic obsolescence.

    From our vantage point in chemical production, it is clear that only generics produced with similar vigilance can keep pace with changing resistance. Fluctuations in drug content, poorly controlled impurities, or out-of-spec release profiles allow resistance to grow unchecked—a burden that falls squarely on the manufacturer. The sustained clinical value of FACTIVE comes from the invisible but crucial adjustments we make batch after batch, based on direct feedback and rigorous trending studies.

    Meticulous Quality in the Manufacturing Setting

    We don’t believe in outsourcing the critical stages. Our chemical engineers handle every step, from raw material receipt to finished batch release. Each production lot undergoes stress testing for heat, moisture, and light, given that many treatment settings can’t guarantee perfect storage. By keeping in-house control over micronisation, blending, tableting, and film-coating, we block the introduction of variable tablet performance seen with far-too-many contract manufacturers or repackagers. This vigilance keeps our product profile tight, with dissolution, strength, and appearance barely drifting over a shelf life that exceeds 36 months under standard storage.

    Our analytic chemists perform HPLC purity checks, screen for known degradants, and validate each output against international reference standards. By running these tests internally, we keep turnaround rapid and spot issues before they escape into distribution. We set aside out-of-spec material and don’t hesitate to investigate rather than pass along substandard output; that policy results from experience repairing earlier generations’ mistakes.

    Safety through Traceability

    The safety of every dose depends on more than formulation—it rests on robust tracking and recall ability. Every FACTIVE tablet can be traced backward through a unique batch coding, right down to the raw material lot and synthesis date. When new safety notices or resistance alerts emerge, we work with the authorities to match concern to the potentially affected distribution batches. This traceability prevents small incidents from becoming major headlines. It creates reassurance for hospitals, who know quick containment backs every prescription.

    For the occasional recall or regulatory question, our production and regulatory teams come together to investigate. The stakes are people’s health, not reputational polish. We have witnessed facilities pay dearly for gaps in their auditing or inconsistency in quality batch records. By investing in comprehensive electronic recordkeeping and batch review processes, we short-circuit problems before they reach the patient level. So far, these choices have reduced regulatory questioning and kept us squarely in good standing in each country where FACTIVE reaches the market.

    Listening to the Field: Our Feedback Loop

    Feedback matters—sometimes it saves lives, sometimes it simply improves the dosing experience. Nurses, pharmacists, and patients relay issues ranging from swallowing comfort to rare events like photosensitivity or tendinopathy. Our pharmacovigilance group aggregates these reports and meets regularly with line supervisors and R&D, not just with quality assurance. We have tweaked excipient blends, tablet size, and coating thickness in direct response to this feedback.

    Simple changes, such as rounding tablet edges or updating color, can make the difference between user acceptance and waste. Years ago, pharmacists alerted us to confusion when tablets of different strengths resembled each other too closely. We marked each tablet to stand out visually, sharply reducing dispensing errors. These modifications come directly from listening to practitioners on the front line—a habit built into our success.

    Transparency with Healthcare Professionals

    Some drugs arrive on the market with little transparency regarding their manufacturing or quality controls. Doctors and pharmacists don’t see what goes on behind company walls. We believe in sharing real production data when questions come from professionals. Our technical bulletins document the exact specifications reached in each batch shipped. Regulatory inspectors have open access to our primary documentation, not just summary certificates.

    This openness doesn’t just check regulatory boxes; it means prescribers gain insight into the clinical tools in hand. As resistance continues to evolve, clinicians rely on verifiable manufacturing practices, not advertising claims. Our willingness to disclose process and quality control information gives prescribers another reason to consider FACTIVE when weighing options for resistant respiratory infections.

    Environmental Responsibility in Production

    Responsibility doesn’t stop at the factory gate. We manage waste and effluent to guard against environmental buildup of antimicrobials—a factor often overlooked, but critical in preventing ecological contributions to resistance. Our wastewater undergoes routine active pharmaceutical ingredient removal, and solid waste incineration meets both local laws and international recommendations. Suppliers for excipients and chemicals receive routine audits to ensure sustainable sourcing.

    This discipline reflects lessons learned across the industry, where unchecked waste sent fluoroquinolone residues into water systems, raising both resistance risk and public concern. Modernizing our containment, handling, and release practices tunes every step toward health and sustainability. These efforts may not feature in every patient leaflet, but they ensure that the benefits of FACTIVE do not come with hidden environmental costs.

    Comparisons with Other Fluroquinolones

    We keep regular benchmarking studies to monitor how gemifloxacin stacks up against other fluoroquinolones. Moxifloxacin and levofloxacin circulate widely, but repeated clinical trials and surveillance studies confirm that gemifloxacin delivers uniquely reliable results against contemporary respiratory pathogens. Pharmacodynamic curves show that gemifloxacin keeps therapeutic concentrations longer at infection sites, especially for certain resistant isolates.

    Older quinolones have shifted towards less responsive patient groups thanks to their side effect profiles or lower respiratory activity. Our teams run stability tests in conditions replicating the hot and humid environments found in several importing nations. Gemifloxacin’s core stability and retained potency under these extremes meet or exceed requirements, translating into genuine clinical reliability in real-world settings—not just under glass-case storage at headquarters.

    Resolving Supply and Shortage Issues

    The pharmaceutical market often contends with shortages, leaving physicians scrambling for alternatives. We have tackled this challenge by maintaining buffer raw material stores, increasing batch sizes in anticipation of predictable spikes (such as flu season), and offering direct-to-hospital delivery programs during crises. Real-time production data lets supply chain supervisors pivot quickly and communicate straight with hospitals if shipments face even minor delays.

    These choices come from direct experience; missing a single week of supply can force hospital clinicians to lean on older, less effective antibiotics. Sustained supply is the backbone of stewardship: doctors are less prone to reach for broad-spectrum or combination agents if they can trust a steady pipeline of effective therapy. Our investments in both redundancy and communication keep FACTIVE present where and when it counts.

    The Future Perspective from the Manufacturer’s Floor

    Antibiotic development and manufacturing demand relentless evolution. Regulatory guidelines grow stricter, while hospital-acquired and community resistance grows more unpredictable. We keep investing in formulation science, bioequivalence testing, and stability research for FACTIVE, finding new ways to make production more robust. Regular collaboration with external clinical teams and internal manufacturing experts drives the next enhancements—sometimes in dissolution rates, sometimes in packaging that better resists environmental challenge.

    The lessons taken from decades producing this fluoroquinolone reinforce our belief that meaningful differentiation relies on more than claims. The exercise of refining every single metric, from batch uniformity to field performance, means our customers do not have to second-guess quality or outcome. FACTIVE Tab., built from science and backed by persistence in every facet of production, gives physicians and patients the result they need—one dependable dose at a time.